



Abram, S. G. F., Palmer, A. J. R., Judge, A., Beard, D. J., & Price, A. J. (2020). Rates of knee arthroplasty in patients with a history of arthroscopic chondroplasty: results from a retrospective cohort study utilising the National Hospital Episode Statistics for England. *BMJ Open*, *10*(4). https://doi.org/10.1136/bmjopen-2019-030609

Publisher's PDF, also known as Version of record License (if available): CC BY Link to published version (if available): 10.1136/bmjopen-2019-030609

Link to publication record in Explore Bristol Research PDF-document

This is the final published version of the article (version of record). It first appeared online via BMJ Publishing Group at https://bmjopen.bmj.com/content/10/4/e030609 . Please refer to any applicable terms of use of the publisher.

# University of Bristol - Explore Bristol Research General rights

This document is made available in accordance with publisher policies. Please cite only the published version using the reference above. Full terms of use are available: http://www.bristol.ac.uk/pure/user-guides/explore-bristol-research/ebr-terms/

# **BMJ Open** Rates of knee arthroplasty in patients with a history of arthroscopic chondroplasty: results from a retrospective cohort study utilising the National Hospital Episode Statistics for England

Simon G F Abram <sup>(1)</sup>, <sup>1,2</sup> Antony J R Palmer, <sup>1,2</sup> Andrew Judge, <sup>1,3,4</sup> David J Beard, <sup>1,2</sup> Andrew J Price <sup>(1)</sup>, <sup>1,2</sup>

**To cite:** Abram SGF, Palmer AJR, Judge A, *et al.* Rates of knee arthroplasty in patients with a history of arthroscopic chondroplasty: results from a retrospective cohort study utilising the National Hospital Episode Statistics for England. *BMJ Open* 2020;**10**:e030609. doi:10.1136/ bmjopen-2019-030609

Prepublication history and additional material for this paper are available online. To view these files, please visit the journal online (http://dx.doi. org/10.1136/bmjopen-2019-030609).

Received 22 March 2019 Revised 25 November 2019 Accepted 13 January 2020

#### Check for updates

© Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY. Published by BMJ.

<sup>1</sup>Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford, UK <sup>2</sup>NIHR Biomedical Research Centre, Oxford, UK <sup>3</sup>Musculoskeletal Research Unit, University of Bristol, Bristol, UK <sup>4</sup>NIHR Biomedical Research Centre, Bristol, UK

#### **Correspondence to**

Dr Simon G F Abram; simon.abram@ndorms.ox.ac.uk

# ABSTRACT

**Objective** The purpose of this study was to analyse the rate of knee arthroplasty in the population of patients with a history of arthroscopic chondroplasty of the knee, in England, over 10 years, with comparison to general population data for patients without a history of chondroplasty.

Design Retrospective cohort study.

Setting English Hospital Episode Statistics (HES) data. Participants and interventions Patients undergoing arthroscopic chondroplasty in England between 2007/2008 and 2016/2017 were identified. Patients undergoing previous arthroscopic knee surgery or simultaneous cruciate ligament reconstruction or microfracture in the same knee were excluded.

**Outcomes** Patients subsequently undergoing a knee arthroplasty in the same knee were identified and mortality-adjusted survival analysis was performed (survival without undergoing knee arthroplasty). A Cox proportional hazards model was used to identify factors associated with knee arthroplasty. Relative risk of knee arthroplasty (total or partial) in comparison to the general population was determined.

Results Through 2007 to 2017, 157 730 eligible chondroplasty patients were identified. Within 1 year, 5.91% (7984/135 197; 95% CI 5.78 to 6.03) underwent knee arthroplasty and 14.22% (8145/57 267; 95% CI 13.94 to 14.51) within 5 years. Patients aged over 30 years with a history of chondroplasty were 17.32 times (risk ratio; 95% Cl 16.81 to 17.84) more likely to undergo arthroplasty than the general population without a history of chondroplasty. **Conclusions** Patients with cartilage lesions of the knee, treated with arthroscopic chondroplasty, are at greater risk of subsequent knee arthroplasty than the general population and for a proportion of patients, there is insufficient benefit to prevent the need for knee arthroplasty within 1 to 5 years. These important new data will inform patients of the anticipated outcomes following this procedure. The risk in comparison to non-operative treatment remains unknown and there is an urgent need for a randomised clinical trial in this population.

# Strengths and limitations of this study

- Strengths of the data source analysed in this study include comprehensive, national, data collection and the ability to match treatment with outcomes, including by the laterality of intervention, over time.
- This is the largest cohort of patients undergoing arthroscopic chondroplasty that has been reported, with strict inclusion criteria, excluding patients with a history of previous surgery to the same knee and those undergoing simultaneous ligament reconstruction or microfracture.
- All studies of this design rely on coding accuracy and some coding errors are inevitable; although outcomes were stratified by a range of patient factors, unmeasured potential confounders include body mass index, limb alignment, baseline radiographic status.
- Knee arthroplasty is an end-stage outcome and will underestimate the true burden and severity of symptomatic osteoarthritis in this population.
- The outcome had these patients not undergone arthroscopic chondroplasty remains unknown.

# INTRODUCTION

Around 2 million knee arthroscopy procedures are performed worldwide each year.<sup>1</sup> Historically, knee washout and 'debridement' was shown to be ineffective for the treatment of advanced osteoarthritis.<sup>2–4</sup> For early osteoarthritis, however, a number of surgical and non-surgical treatments are available and treatment selection is challenging.<sup>5</sup> The aim of treatment in these cases is to improve symptoms and delay or prevent progressive osteoarthritis.<sup>6</sup>

Chondroplasty is a non-specific term that encompasses several techniques for the treatment of cartilage defects.<sup>7</sup> It includes debridement and abrasion using mechanical 'shavers' and, more recently, thermal or radiofrequency techniques have also emerged despite some concerns these techniques might risk inducing localised chondrocyte death.<sup>7-11</sup> Recent national guidance was cautiously supportive of radiofrequency chondroplasty for the treatment of 'discrete chondral defects' based on a small number of clinical trials comparing the outcomes of mechanical and radiofrequency techniques.<sup>12</sup> It is not known which patients are most likely to benefit from chondroplasty procedures and when the procedure does not provide sustained benefit, knee arthroplasty is often indicated. The success rate of chondroplasty is, however, poorly understood and the proportion of patients undergoing subsequent knee arthroplasty after this intervention has been unknown.

The purpose of this study was to determine the proportion of patients undergoing knee chondroplasty procedures that subsequently receive a knee arthroplasty in the same knee, with specific focus on the proportion of patients undergoing early arthroplasty with 1 year or 2 years of chondroplasty. Factors associated with the risk of subsequent arthroplasty are reported and the relative risk in comparison to the general population determined.

#### METHODS Data source

National Hospital Episode Statistics (HES) data was obtained (application DARS-NIC-68703) in a de-identified (pseudoanonymised) format from National Health Service (NHS) Digital.<sup>13</sup> HES contains a record of de-identified patient attendances at NHS hospitals in England.<sup>13</sup> The data is submitted by hospitals to claim payment for the services they provide and is also intended for secondary use, including research. HES includes episodes of care delivered in treatment centres (including those in the independent sector) funded by the NHS, episodes of care in England where patients are resident outside of England and privately funded patients treated within NHS England hospitals. The information recorded in the HES database includes patient demographic and residence data, primary and secondary diagnoses including comorbidities, and all procedures undertaken.

#### **Procedures**

All HES records between 1 April 2007 and 31 March 2017 were extracted for patients undergoing arthroscopic chondroplasty. Patients undergoing previous arthroscopic knee surgery or simultaneous cruciate ligament reconstruction or microfracture in the same knee were excluded. Procedures were identified using the Classification of Surgical Operations and Procedures (OPCS-4) codes recorded within the HES data (see online supplementary appendix 1 for OPCS-4 code list).<sup>14</sup> All knee arthroplasty (partial or total) procedures were also identified (online supplementary appendix 2) for the whole population to enable the relative risk of knee arthroplasty with and without a history of chondroplasty to be determined.

#### Outcomes

The primary outcome was knee arthroplasty, matched to the side of any previous chondroplasty (using recorded OPCS-4 laterality codes).

### **Statistical analysis**

Stata V.15.1 (StataCorp, College Station, Texas, USA) was used to perform all analysis. In accordance with Office for National Statistics (ONS) and NHS Digital guidance, rates where the number of events was less than six were suppressed.<sup>15</sup> Procedures with date errors or missing laterality were excluded. The absolute rate of knee arthroplasty was determined at 1 year, 2 years, 5 years and 8 years following arthroscopic chondroplasty as the proportion of the cohort with this minimum period of follow-up. Mortality adjusted Kaplan-Meier survival analysis (survival was defined as not undergoing knee arthroplasty) was also performed and stratified by patient age group and sex.

A Cox proportional hazards model was used first to calculate the unadjusted HR of knee arthroplasty over time by age group, sex, index of multiple deprivation (quintile derived from regional factors in England including average income, employment, education, housing and crime; 1=least deprived area, 5=most deprived), ethnicity, modified Charlson comorbidity index (derived with maximum 5-year diagnosis code lookback period),<sup>16–18</sup> year of treatment (chondroplasty), rurality and ethnicity, respectively.<sup>16–19</sup> The HRs were then adjusted including all these variables in the model.

The relative risk (risk ratio) of knee arthroplasty in the population of patients with a history of chondroplasty in comparison to the general population (without a history of chondroplasty) was estimated for the year 2016 to 2017. All patients undergoing knee arthroplasty in 2016 to 2017 were identified and the number of these patients with a recorded previous chondroplasty (in the prior 10 years of HES data), versus those without, made up the numerator for each respective population. The chondroplasty population denominator was the number of patients with a history of chondroplasty that had not undergone a knee arthroplasty prior to 2016 to 2017. The denominator for the non-chondroplasty population was the ONS mid-year population estimate less the chondroplasty population.

#### Patient and public involvement

There was no patient and public involvement in this study.

# RESULTS

Over the study period, 157 730 chondroplasty patients were identified as eligible for analysis (figure 1). The mean age of the chondroplasty cohort was 51.7 year (SD 13.8) and 48.1% were female (table 1). Over the same period, 604 056 patients underwent knee arthroplasty, of




Figure 1 Flow chart illustrating extraction of patient level cohort.

which 35 916 (5.95%) had a record of a previous chondroplasty (table 1).

Overall, following chondroplasty, 5.91% (7984/135 197; 95% CI 5.78 to 6.03) patients underwent knee arthroplasty within 1 year, 9.41% (10 787/114 592; 95% CI 9.24 to 9.58) within 2 years, 14.22% (8145/57 267; 95% CI 13.94 to 14.51) within 5 years and 17.61% (2879/16 347; 95% CI 17.03 to 18.20) within 8 years (table 2). The risk of arthroplasty was greater in female patients (adjusted HR 1.38; 95% CI 1.34 to 1.42) and in older patients (adjusted HR 1.33 per 5 years; 95% CI 1.32 to 1.34) (table 3, figure 2; figure 3). Patients with a greater comorbidity index were also at increased risk of subsequently undergoing arthroplasty (adjusted HR 1.03 per five units Charlson index; 95% CI 1.01 to 1.05).

The risk of knee arthroplasty after chondroplasty fell slightly over time, by year of chondroplasty treatment (adjusted HR 0.95 per 5 years; 95% CI 0.92 to 0.98). Patients in regions of increased deprivation and patients of white ethnicity were at greater risk of subsequent arthroplasty (table 2). Patients undergoing concurrent meniscal surgery were also at greater risk of subsequent arthroplasty (adjusted HR 1.09; 95% CI 1.06 to 1.13).

In 2016 to 2017, the rate of knee arthroplasty was 3.49% (95% CI 3.39 to 3.60) in patients (aged 30 or older) with a recorded history of chondroplasty and 0.20% (95% CI 0.19 to 0.20) in patients without a record of chondroplasty. This corresponded to an overall relative risk of knee arthroplasty for the chondroplasty cohort patients of 17.32 times (risk ratio (RR); 95% CI 16.81 to 17.84) that of the general population (table 4).

Although the absolute annual rate of knee arthroplasty was low, the relative risk of undergoing knee arthroplasty at a younger age was greatly elevated in comparison to arthroplasty at an older age, as shown in table 4. Patients aged 30 to 39 with a history of a previous chondroplasty were 170.92 times (RR; 95% CI 116.72 to 250.30) more likely to undergo knee arthroplasty than the general population, per year, in comparison to 11.09 times (RR; 95% CI 10.42 to 11.80) more likely for the over 69 age group.

**Open access** 

# DISCUSSION

# **Principal findings**

Patients undergoing chondroplasty procedures of the knee have a 17 times increased risk of receiving a knee arthroplasty compared with the general population. Nearly 10% of patients will have received a knee arthroplasty within 2 years of the chondroplasty procedure. The relative risk of undergoing arthroplasty at a young age is particularly elevated, reaching 171 times the general population rate for arthroplasty between the ages of 30 and 39 years of age. For a proportion of patients, the results indicate insufficient benefit to prevent the need for knee arthroplasty within 1 or 2 years, but the risk had these patients not undergone chondroplasty remains unknown.

# **Comparison to other studies**

We previously reported trends in chondroplasty surgery in England, but data from other countries is not available.<sup>20</sup> The age-sex standardised rate of chondroplasty increased 191% from 17.6/100 000 (95% CI 17.2 to 18.0) in 2007/2008 to 51.2/100 000 (95% CI 50.6 to 51.7) in 2016/2017.<sup>20</sup> The rate of chondroplasty was greatest in patients aged 40 to 59 years (increasing 210% from 34.3/100 000 in 2007/2008 to 106.4/100 000 in 2016/2017.<sup>20</sup>

In England, although national guidance has been cautiously supportive of radiofrequency chondroplasty for specific indications, there is only limited evidence demonstrating the effectiveness of chondroplasty compared with alternative surgical or non-surgical treatments.<sup>12</sup> The only randomised studies have been limited to comparisons of different chondroplasty techniques.<sup>1012</sup> Long-term outcomes following chondroplasty have yet to be reported.<sup>12</sup>

Older patients are much more likely to have generalised osteoarthritis, rather than 'discrete chondral defects' for which the national guidance supports radiofrequency chondroplasty.<sup>12</sup> <sup>21</sup> For more generalised osteoarthritis, chondroplasty is analogous to debridement and washout, where multiple clinical trials demonstrate no benefit.<sup>2-4</sup> The use of chondroplasty in the treatment of patients with more generalised chondral pathology is therefore unproven and not recommended.<sup>22</sup> In our study, there was considerable age-group variation in outcomes, with 18.8% of patients aged 60 to 79 years undergoing arthroplasty within 2 years of chondroplasty, in comparison to 0.43% for patients undergoing chondroplasty aged 20 to 39 years. This observation is consistent with the presence of more established osteoarthritis in older age groups.

Female patients were observed to be of greater risk of subsequent arthroplasty in our study. This has previously been observed following knee arthroscopy in the USA.<sup>23</sup>

-1 -1 -

. .. ..

	Chondrop	lasty cohort	Knee arthroplasty cohort			
	All cases		No previou	s chondroplasty	Previous ch	ondroplasty
	n	%	n	%	n	%
Total	157 730	100.00	568 140	94.05	35 916	5.95
Sex						
Male	81 884	51.91	244 684	43.07	15 512	43.19
Female	75 846	48.09	323 456	56.93	20 404	56.81
Age group (years)						
<20	2868	1.82	1179	0.21	1	<0.01
20–39	24 648	15.63	1568	0.28	353	0.98
40–59	83 258	52.79	85 797	15.1	14 023	39.04
60–79	45 191	28.65	400 541	70.5	20 361	56.69
80+	1765	1.12	79 055	13.91	1178	3.28
Charlson comorbidity index	(					
0	121 605	77.10	534 399	94.06	27 331	76.1
1–15	34 719	22.01	31 683	5.58	8175	22.76
16–30	1296	0.82	1879	0.33	393	1.09
31–50	110	0.07	179	0.03	17	0.05
Index of multiple deprivatio	n (quintiles)					
1=least deprived	36 043	23.21	121 813	21.44	7921	22.05
2	35 189	22.66	127 672	22.47	7938	22.1
3	32 493	20.92	123 160	21.68	7806	21.73
4	27 312	17.59	103 236	18.17	6372	17.74
5=most deprived	24 266	15.62	85 283	15.01	5416	15.08
Missing	2427		6976		463	
Rurality						
Urban	119 766	76.42	423 895	74.61	27 157	75.61
Rural	36 953	23.58	141 271	24.87	8634	24.04
Missing	1011		2974		125	
Ethnicity						
White	141 928	94.43	525 934	92.57	34 349	95.64
Mixed	953	0.63	1844	0.32	115	0.32
Asian	4511	3.00	19 203	3.38	804	2.24
Black	2122	1.41	5840	1.03	193	0.54
Other	792	0.53	1367	0.24	68	0.19
Missing	7424		13 952		387	
Concurrent procedures						
None	65 987	41.84	-	-	-	-
Meniscal	91 743	58.16	-	-	-	-

Patients of white ethnicity and greater deprivation were also at greater risk in our cohort. These findings may reflect differences in healthcare access including treatment thresholds for either the chondroplasty or knee arthroplasty, or differences in care seeking behaviour which has been shown to be influenced by socioeconomic, cultural, occupational and psychological factors, or there could be biological factors underlying the observation.<sup>24–26</sup>

Patients with a greater comorbidity index were more likely to undergo subsequent arthroplasty, and the reason for this is unclear. One possible explanation might be an association between comorbidity and higher body mass index (BMI), which is not recorded in this data set, with patients having a greater BMI being more likely to progress to endstage osteoarthritis, or that these patients had more severe pathology at the time of their index chondroplasty.<sup>27</sup>

n $\Gamma$ (A         % (95% cl)         n $\Gamma$ (A         % (95% cl)         n $\Gamma$ (A         % (95% cl)           Total         135 197         7984         5.91% (5.78 to 6.03)         114 592         10.787         9.41% (9.24 to 8.24 to 9.24	1-year outcome* 2-year outcome* 5-year outcome*	itcome*	Ċ	8-year outcome*	e*
135 197         7984         5.91% (5.78 to 6.03)         114 592         10         787           alle         69<787         3160         4.53% (4.37 to 4.68)         59<101         4261           male         65<410         4824         7.38% (7.18 to 7.58)         55<491         6526           group         versity         -         -         -         -         -           39<21         4824         7.38% (7.18 to 7.58)         55<491         6526         4049           9         21548         48         0.22% (0.16 to 0.30)         18.626         4049           -59         72         35<73         55<491         6974         4049           -59         72         367         3568         6343         79           -59         72         365         514% (5.00 to 5.27)         89<081         736           +         1563         289         514% (5.00 to 5.27)         89<081         736           +         16453         284         1.106         73         136           +         1566         514% (5.00 to 5.27)         89<081         136           +         104         537% (8.06 to 8.69)         2454         736<	n TKA % (95% Cl) n	n TKA %	% (95% Cl) n	n TKA	A % (95% CI)
787       3160       4.53% (4.37 to 4.68)       59 101       4261         410       4824       7.38% (7.18 to 7.58)       55 491       6526         410       4824       7.38% (7.18 to 7.58)       55 491       6526         548       48       0.22% (0.16 to 0.30)       18 583       79         345       2654       3.67% (3.53 to 3.81)       60 974       4049         341       4994       12.57% (12.24 to       33 680       6343         563       288       18.43% (16.53 to       1355       316         6114       4994       12.57% (12.24 to       33 680       6343         6114       4994       12.57% (12.24 to       33 680       6343         6114       4994       12.57% (10.63 to       33 680       6343         6114       4094       13.56       316       316         6114       409       13.55       316       316         6114       4049       20.44)       1355       316         6114       4048       6.004 0.62.01       8908       149         6114       4049       2.14% (5.00 0.62.01       24540       256         702       2464       2.52% (10.63 0.62.01		8145 14 14	14.22% (13.94 to 16 14.51)	16 347 2879	17.61% (17.03 to 18.20)
787       3160       4.53% (4.37 to 4.68)       59 101       4261         410       4824       7.38% (7.18 to 7.58)       55 491       6526         410       4824       7.38% (7.18 to 7.58)       55 491       6526         548       48       0.22% (0.16 to 0.30)       18 583       79         548       48       0.22% (0.16 to 0.30)       18 583       79         345       2654       3.67% (3.53 to 3.81)       60 974       4049         741       4994       12.57% (12.24 to       33 680       6343         563       288       18.43% (16.53 to       1355       316         611Y       12.90)       12.50% (10.63 to       1355       316         611Y       12.90)       20.44)       33 680       6343         611Y       12.50% (10.63 to       33 680       5368       136         611Y       14.62)       20.44)       73 68       136         611Y       14.62)       11.11% (5.46 to       73       13         610       11.11% (5.46 to       73       13       13         610       10       11.11% (5.46 to       73       13         610       11.11% (5.46 to       73					
410       4824       7.38% (7.18 to 7.58)       55 491       6526         -       -       -       -       -         548       48       0.22% (0.16 to 0.30)       18 583       79         345       2654       3.67% (3.53 to 3.81)       60 974       4049         741       4994       12.57% (12.24 to       33 680       6343         753       2863       18.43% (16.53 to       1355       316         610       12.900       1355       316       3268         611       4994       12.50% (10.63 to       1355       316         611       1290       5.14% (5.00 to 5.27)       89 081       7366         611       1290       5.14% (5.00 to 5.27)       89 081       7366         611       1290       5.14% (5.00 to 5.27)       89 081       7366         611       1280       6.14% (5.00 to 5.27)       89 081       7366         611       138       12.52% (10.63 to 7.24)       89 081       7366         612       837% (8.06 to 8.69)       2454       736       736         610       11.11% (5.46 to       73       73       137         610       11.11% (5.46 to       73		3315 11 11	11.17% (10.81 to 11.53)	8514 1208	14.19% (13.45 to 14.95)
-         -	6526	4830 17 17	17.51% (17.07 to 17.97)	7833 1671	21.33% (20.43 to 22.26)
- $  -$ <					
.16 to 0.30)18 583793.53 to 3.81)60 97440493.53 to 3.81)60 9744049(12.24 to33 6806343(16.53 to13553165.00 to 5.27)89 08173665.00 to 5.27)89 08173665.69 to 6.23)26 54624055.65 to 6.26)23 72123245.65 to 6.26)23 72123245.65 to 6.26)29 72223245.65 to 6.26)29 7222324		I		1	I
3.53 to 3.81)60 9744049(12.24 to33 6806343(15.53 to1355316(16.53 to13553165.00 to 5.27)89 08173665.00 to 5.27)89 08173663.06 to 8.69)24 54032283.06 to 8.69)24 5403228(10.63 to898180(10.63 to898180(10.63 to898180(10.63 to898180(5.46 to7313(5.46 to7313(5.46 to26 54624055.69 to 6.23)25 63824095.93 to 6.50)23 72123245.65 to 6.26)23 72123245.65 to 6.26)23 72123245.65 to 6.26)23 7212324		95 0.9	0.95% (0.77 to 1.16)	3094 53	1.71% (1.29 to 2.23)
(12.24 to33 6806343(16.53 to1355316(16.53 to13553165.00 to 5.2789 08173665.00 to 5.2789 08173663.06 to 8.6924 5403228(10.63 to898180(10.63 to898180(10.63 to898180(5.46 to7313(5.46 to7313(5.46 to7313(5.46 to7313(5.46 to7324055.69 to 6.2325 63824055.93 to 6.5023 72123245.65 to 6.2619 7021913		3327 11 11	11.15% (10.79 to 11.51)	8552 1287	15.05% (14.30 to 15.82)
(16.53 to13553165.00 to 5.27)89 08173665.00 to 5.27)89 08173663.06 to 8.69)24 54032283.06 to 8.69)24 540328(10.63 to898180(10.63 to898180(5.46 to7313(5.46 to7313(5.46 to7313(5.46 to7313(5.46 to7324055.68 to 6.21)26 54624055.69 to 6.23)25 63824095.93 to 6.50)23 72123245.65 to 6.26)23 72123245.65 to 6.26)29 7021913	6343	4522 27 27	27.05% (26.38 to 27.73)	4508 1479	32.81% (31.44 to 34.20)
5.00 to 5.27)89 08173663.06 to 8.69)24 54032283.06 to 8.69)24 5403228(10.63 to898180(10.63 to898180(5.46 to7313(5.46 to7313(5.46 to7313(5.46 to7313(5.46 to26 54624055.69 to 6.23)25 63824095.93 to 6.50)23 72123245.65 to 6.26)19 7021913	316	201 28 32	28.59% (25.28 to 32.09)	193 60	31.09% (24.64 to 38.13)
5.00 to 5.27)89 08173663.06 to 8.69)24 54032283.06 to 8.69)24 54013(10.63 to7313(5.46 to7313(5.46 to7313(5.46 to7324055.68 to 6.21)26 54624055.69 to 6.23)25 63824095.93 to 6.50)23 72123245.65 to 6.26)19 7021913					
3.06 to 8.69)     24 540     3228       (10.63 to     898     180       (5.46 to     73     13       (5.46 to     73     2405       5.69 to 6.23)     25 638     2409       5.93 to 6.50)     23 721     2324       5.65 to 6.26)     23 721     2324		5837 12 13	12.83% (12.52 to 10 13.14)	13 362 2148	16.08% (15.46 to 16.71)
(10.63 to898180(5.46 to7313(5.46 to73135.68 to26 54624055.69 to25 63824095.93 to25 63824095.93 to25 638237215.93 to23 72123245.65 to26519 702	3228	2207 19 20	19.41% (18.69 to 20.15)	2884 701	24.31% (22.75 to 25.91)
(5.46 to     73     13       5.68 to 6.21)     26 546     2405       5.69 to 6.23)     25 638     2409       5.93 to 6.50)     23 721     2324       5.93 to 6.50)     23 721     2324       5.65 to 6.26)     19 702     1913	180	101 25 30	25.83% (21.56 to 30.47)	101 30	29.70% (21.02 to 39.61)
5.68 to 6.21)     26 546     2405       5.69 to 6.23)     25 638     2409       5.93 to 6.50)     23 721     2324       5.65 to 6.26)     19 702     1913	13	I I		I	I
31         054         1846         5.94%         (5.68 to 6.21)         26         2405         2405           30         218         1799         5.95%         (5.69 to 6.23)         25         638         2409           27         974         1737         6.21%         (5.93 to 6.50)         23         721         2324           23         312         1387         5.95%         (5.65 to 6.26)         19         702         1913					
30 218       1799       5.95% (5.69 to 6.23)       25 638       2409         27 974       1737       6.21% (5.93 to 6.50)       23 721       2324         23 312       1387       5.95% (5.65 to 6.26)       19 702       1913		1835 13 14	13.67% (13.09 to 14.26)	3878 629	16.22% (15.07 to 17.42)
27 974       1737       6.21% (5.93 to 6.50)       23 721       2324       9.80%         10.18)       10.18       10.18       10.18         23 312       1387       5.95% (5.65 to 6.26)       19 702       1913       9.71%		1779 13 14	13.88% (13.28 to 14.49)	3474 617	17.76% (16.50 to 19.07)
23 312 1387 5.95% (5.65 to 6.26) 19 702 1913 9.71%	2324	1772 14 15	14.98% (14.34 to 15.63)	3374 635	18.82% (17.51 to 20.18)
10.13)	1913 9.71% (9.30 to 9771 10.13)	1420 14 15	14.53% (13.84 to 15.25)	2762 496	17.96% (16.54 to 19.44)

6

5

BMJ Open: first published as 10.1136/bmjopen-2019-030609 on 16 April 2020. Downloaded from http://bmjopen.bmj.com/ on April 23, 2020 by guest. Protected by copyright.

Table 2	Continued											
	1-year outcome*	utcom	e*	2-year ou	outcome*		5-year outcome*	utcome*		8-year outcome*	utcome	*
	Ę	n TKA	% (95% CI)	c	n TKA	% (95% CI)	c	n TKA	% (95% CI)	c	n TKA	n TKA % (95% Cl)
ъ	20 591	1104	5.36% (5.06 to 5.68)	17 194	1588	9.24% (8.81 to 9.68)	8420	1197	14.22% (13.48 to 14.98)	2451	444	18.12% (16.61 to 19.70)
Rurality												
Urban	102 665	6004	5.85% (5.71 to 5.99)	86 807	8135	9.37% (9.18 to 9.57)	43 287	6148	14.20% (13.88 to 14.54)	2154	12 242	17.60% (16.92 to 18.28)
Rural	31 760	1944	6.12% (5.86 to 6.39)	27 127	2613	9.63% (9.28 to 9.99) 13 739	13 739	1980	14.41% (13.83 to 15.01)	713	3987	17.88% (16.70 to 19.11)
Ethnicity												
White	122 261	7672	6.28% (6.14 to 6.41) 103 979	103 979	10 366	9.97% (9.79 to 10.15)	52 267	7834	14.99% (14.68 to 15.30)	14 908	2750	18.45% (17.83 to 19.08)
Mixed	750	21	2.80% (1.74 to 4.25)	609	32	5.25% (3.62 to 7.34)	278	22	7.91% (5.03 to 11.74)	76	ω	10.53% (4.66 to 19.69)
Asian	3722	130	3.49% (2.93 to 4.13)	3088	186	6.02% (5.21 to 6.92)	1465	167	11.40% (9.82 to 13.14)	362	75	20.72% (16.66 to 25.26)
Black	1770	27	1.53% (1.01 to 2.21)	1466	53	3.62% (2.72 to 4.70)	677	38	5.61% (4.00 to 7.62)	171	15	8.77% (4.99 to 14.06)
Other	645	15	2.33% (1.31 to 3.81)	518	18	3.47% (2.07 to 5.44)	250	21	8.40% (5.27 to 12.55)	75	0	12.00% (5.64 to 21.56)
Concurrer	Concurrent procedures	Ş										
None	57 208	2686	4.70% (4.52 to 4.87)	50 256	3754	7.47% (7.24 to 7.70) 28 578	28 578	3252	11.38% (11.01 to 11.75)	9370	1389	14.82% (14.11 to 15.56)
Meniscal	al 77 989	5298	6.79% (6.62 to 6.97)	64 336	7033	10.93% (10.69 to 11.18)	28 689	4893	17.06% (16.62 to 17.50)	6977	1490	21.36% (20.40 to 22.34)
<ul> <li>– =suppres</li> <li>*Excluding</li> </ul>	<ul> <li>=suppressed due to small numbers</li> <li>*Excluding those patients where the</li> </ul>	nall num s where	-=suppressed due to small numbers "Excluding those patients where the date of their procedure was less than this number of years from the end of the observation period in the data set.	re was less	than this	number of years from the	end of the	observatio	on period in the data set.			

TKA, total or partial knee arthroplasty.

6

following an	throscopic	chondroplasty			
	Unadjust subseque		Adjusted risk subsequent TKA		
	HR	95% CI	HR	95% CI	
Sex					
Male	1.00	1.00	1.00	1.00	
Female	1.61	1.57 to 1.66	1.38	1.34 to 1.42	
Age (per 5 y	vears)				
Per year	1.35	1.35 to 1.36	1.33	1.32 to 1.34	
Year of treat	tment (per	5 years)			
Year	0.99	0.96 to 1.03	0.95	0.92 to 0.98	
Charlson co	morbidity i	ndex (per five (	units)		
Charlson index	1.29	1.27 to 1.31	1.03	1.01 to 1.05	
Index of mu	ltiple depri	vation (quintile)	)		
1=least	1.00	1.00	1.00	1.00	
2	1.03	0.99 to 1.08	1.07	1.03 to 1.12	
3	1.08	1.04 to 1.13	1.17	1.12 to 1.22	
4	1.03	0.99 to 1.08	1.20	1.15 to 1.26	
5=most	1.01	0.96 to 1.06	1.29	1.23 to 1.36	
Rurality					
Urban	1.00	1.00	1.00	1.00	
Rural	1.03	1.00 to 1.07	0.99	0.95 to 1.02	
Ethnicity					
White	1.00	1.00	1.00	1.00	
Mixed	0.50	0.38 to 0.65	0.66	0.51 to 0.86	
Asian	0.65	0.59 to 0.72	0.73	0.66 to 0.81	
Black	0.35	0.28 to 0.42	0.44	0.36 to 0.54	
Other	0.34	0.24 to 0.48	0.45	0.32 to 0.64	
Concurrent	procedures	5			
None	1.00	1.00	1.00	1.00	
Meniscal surgery	1.52	1.48 to 1.57	1.09	1.06 to 1.13	

 Table 3
 Unadjusted and adjusted\* risk of knee arthroplasty

 following arthroscopic chondroplasty

\*Adjusted by all variables in the table.

†Age <20 years suppressed due to small numbers.


TKA, total or partial knee arthroplasty.

Patients undergoing concurrent meniscal surgery were also more likely to undergo subsequent arthroplasty, which is expected given the association between meniscal injury, osteoarthritis and knee arthroplasty.<sup>28</sup>


Recently, there has been renewed focus on the importance of and requirements for individualised patient consent.<sup>29</sup> Our findings make an important contribution to the current evidence, and patients can now be appropriately counselled and consented with knowledge of anticipated long-term outcomes.

# **Strength and limitations**


A key strength of our study is the identification of all knee chondroplasty procedures performed in the National



**Figure 2** Survival curve (not undergoing knee arthroplasty) following chondroplasty by age<sup>+</sup>



Health Service over a 10-year period, creating the largest reported cohort of patients receiving this procedure. Patients with a history of prior arthroscopy in the same



**Figure 3** Survival curve (not undergoing knee arthroplasty) following chondroplasty by sex.

Age groups < 20 years and 80+ years suppressed due to small numbers

Prior chondroplasty		Without prior	Without prior chondroplasty		Relative risk	
Age at TKA (years)	Annual rate TKA/100 k	95% CI	Annual rate TKA/100 k	95% CI	RR	95% CI
30–39	274.48 (0.27%)	190.16 to 383.35 (0.19% to 0.38%)	1.60 (0.00%)	1.32 to 1.92 (0.00% to 0.00%)	170.92	116.72 to 250.30
40–49	1454.02 (1.45%)	1318.04 to 1600.06 (1.32% to 1.60%)	19.79 (0.02%)	18.79 to 20.82 (0.02% to 0.02%)	72.45	65.00 to 80.76
50–59	3626.62 (3.63%)	3448.20 to 3811.60 (3.45% to 3.81%)	130.68 (0.13%)	128.05 to 133.35 (0.13% to 0.13%)	26.82	25.41 to 28.30
60–69	5179.17 (5.18%)	4933.67 to 5433.20 (4.93% to 5.43%)	386.68 (0.39%)	381.64 to 391.77 (0.38% to 0.39%)	12.78	12.16 to 13.44
70+	6090.50 (6.09%)	5721.53 to 6475.82 (5.72% to 6.48%)	520.46 (0.52%)	514.89 to 526.07 (0.51% to 0.53%)	11.09	10.42 to 11.80
Overall (30+)	3494.61 (3.49%)	3394.82 to 3596.52 (3.39% to 3.60%)	195.38 (0.20%)	193.90 to 196.87 (0.19% to 0.20%)	17.32	16.81 to 17.84

TKA, total or partial knee arthroplasty; RR, risk ratio.

knee, simultaneous ligament reconstruction or microfracture were excluded as potential confounding factors. It should still be noted that patients undergoing non-NHS treatment, for example, knee arthroplasty in the private sector after a previous knee arthroscopy under NHS care, would not be captured in this data set and the number of these procedures performed in the private sector is currently unknown. National data does indicate, however, that private healthcare expenditure as a proportion of total healthcare expenditure has remained relatively stable at around 17% to 18% of total health expenditure between 2005 and 2015.30 For all observational studies utilising large data sets there may be some concerns raised about coding accuracy. The data in our study was cleaned prior to analysis, excluding patients where procedures were missing the side of intervention and cases where date coding errors were identified. Although some other data coding errors are inevitable, data errors in procedure coding would result in hospitals not receiving payment for surgery performed, and this provides a strong incentive for data accuracy with regards to the coding data analysed in this study.

We were able to stratify risk of arthroplasty by a large number of patient factors, but certain procedure specific data is not recorded. Operative factors, such as the affected compartment of the knee and extent of initial cartilage damage before intervention, are not recorded in this database. These factors may be important in determining outcome, for example, there are likely to be differences in long-term outcomes between chondroplasty performed to the tibiofemoral joint in comparison to the patellofemoral joint.<sup>31</sup> Other unmeasured sources of potential confounding include BMI, leg alignment and radiographic status at the time of intervention. These are important considerations when considering if a patient is suitable for chondral surgery intervention, but the specific impact of these factors on long-term outcomes in this population remains uncertain. Subjective, patient-reported, symptomatic outcome data is not vet available for this cohort and radiographic outcomes are not recorded in the HES database. Instead, our study focussed on the objective, measurable outcome of knee arthroplasty, matched to the same knee as the previous chondroplasty surgery intervention. Although knee arthroplasty represents the end-stage of symptomatic failure for patients with osteoarthritis, it is likely to considerably underestimate the overall health and symptom burden in this cohort. Patients, particularly younger patients, may not have been willing or suitable candidates for knee arthroplasty, and the threshold for arthroplasty may have been much higher for younger age groups or older patients with multiple comorbidities. It is also important to note that, in general, 'chondroplasty' is a non-specific term that encompasses several techniques for the debridement of cartilage defects.<sup>7</sup> The findings in this paper cannot be generalised to other types of arthroscopic and joint preservation surgery, cartilage repair and regeneration techniques, such as microfracture and autologous chondrocyte implantation.<sup>631</sup>

Our study represents a high-risk cohort of patients with cartilage damage. It is unknown from this observational data whether undergoing the chondroplasty procedure was beneficial to the symptoms or prognosis of these individuals over the full study period. That is, it is not known whether the chondroplasty procedure delayed or prevented arthroplasty in those patients that did not undergo arthroplasty (approximately 86% by 5 years), in which case delivery of the intervention may have been cost-effective, or the converse interpretation is that the procedure may have been overused and that the natural history of symptomatic osteoarthritis in this population was unaltered. For example, the observed proportion of patients undergoing arthroplasty (6%) is suggestive of suboptimal treatment selection. These individuals are highly unlikely to have had only localised or partial thickness lesions and our results may indicate that knee arthroplasty may have been a more appropriate treatment. Nevertheless, the symptomatic outcome in the patients that did not undergo arthroplasty is not known and the answer to whether the procedure is cost-effective with optimal patient selection is unknown and requires evaluation in a high-quality randomised controlled trial with a non-operative treatment arm. Such a trial should help to evaluate the optimal indications for chondroplasty, assess the relative rate of progression of treated chondral damage with versus without chondroplasty and ultimately determine whether appropriate use of chondroplasty is beneficial to patient outcome including, potentially, the long-term demand for knee arthroplasty.

Our study reports the long-term outcomes following chondroplasty in a high-risk cohort of patients with cartilage damage for the first time. Our findings stratified by a range of patient-specific factors however further work is required to optimise treatment selection and additional patient information may allow more accurate prediction of outcome and guide clinical management.

#### CONCLUSION

The risk of knee arthroplasty is 17 times greater in patients with a history of knee chondroplasty and in a proportion of patients, there is insufficient benefit to prevent the need for knee arthroplasty within 1 or 2 years. These important new data help inform patients and clinicians of the long-term outcomes following this procedure, at the population level, for the first time. Enhanced clinical guidance on the appropriate indications for chondroplasty are required and there is a need for high-quality randomised studies to determine the relative clinical and cost-effectiveness of this intervention in comparison to alternative, including non-surgical, treatments.

Twitter Simon G F Abram @simonabram and Antony J R Palmer @AJRPalmer

**Contributors** SGFA: concept, methodology, analysis, writing and editing paper, guarantor. AJRP: writing and editing paper. AJ: methodology, analysis and editing paper. DB: concept and editing paper. AJP: concept, methodology and editing paper.

**Funding** The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.

**Competing interests** AJ has received consultancy fees from Freshfields Bruckhaus Deringer (on behalf of Smith & Nephew Orthopaedics Limited), and is a member of the Data Safety and Monitoring Board (which involved receipt of fees) from Anthera Pharmaceuticals, Inc. All other authors declare no financial relationships with any organisations that might have an interest in the submitted work in the previous 3 years, no other relationships or activities that could appear to have influenced the submitted work.

Patient consent for publication Not required.

Provenance and peer review Not commissioned; externally peer reviewed.

Data availability statement No additional data is available.

**Open access** This is an open access article distributed in accordance with the Creative Commons Attribution 4.0 Unported (CC BY 4.0) license, which permits others to copy, redistribute, remix, transform and build upon this work for any purpose, provided the original work is properly cited, a link to the licence is given,

#### **ORCID** iDs

Simon G F Abram http://orcid.org/0000-0002-4452-6499 Andrew J Price http://orcid.org/0000-0002-4258-5866

#### REFERENCES

- 1 Järvinen TLN, Guyatt GH. Arthroscopic surgery for knee pain. *BMJ* 2016;354:i3934.
- 2 Kirkley A, Birmingham TB, Litchfield RB, et al. A randomized trial of arthroscopic surgery for osteoarthritis of the knee. N Engl J Med 2008;359:1097–107.
- 3 Moseley JB, O'Malley K, Petersen NJ, *et al*. A controlled trial of arthroscopic surgery for osteoarthritis of the knee. *N Engl J Med* 2002;347:81–8.
- 4 Aaron RK, Skolnick AH, Reinert SE, et al. Arthroscopic débridement for osteoarthritis of the knee. J Bone Joint Surg Am 2006;88:936–43.
- 5 Palmer JS, Monk AP, Hopewell S, et al. Surgical interventions for early structural knee osteoarthritis. Cochrane Database Syst Rev;20.
- 6 Mistry H, Connock M, Pink J, *et al.* Autologous chondrocyte implantation in the knee: systematic review and economic evaluation. *Health Technol Assess* 2017;21:1–294.
- 7 Barber FA, Iwasko NG. Treatment of grade III femoral chondral lesions: mechanical chondroplasty versus monopolar radiofrequency probe. *Arthroscopy* 2006;22:1312–7.
- 8 Allen RT, Tasto JP, Cummings J, *et al*. Meniscal debridement with an arthroscopic radiofrequency wand versus an arthroscopic shaver: comparative effects on menisci and underlying articular cartilage. *Arthroscopy* 2006;22:385–93.
- 9 Spahn G, Kahl E, Mückley T, et al. Arthroscopic knee chondroplasty using a bipolar radiofrequency-based device compared to mechanical shaver: results of a prospective, randomized, controlled study. Knee Surg Sports Traumatol Arthrosc 2008;16:565–73.
- 1 Lu Y, Edwards RB, Cole BJ, et al. Thermal chondroplasty with radiofrequency energy. An in vitro comparison of bipolar and monopolar radiofrequency devices. Am J Sports Med 2001;29:42–9.
- 11 Dandy DJ. Abrasion chondroplasty. Arthroscopy 1986;2:51–3.
- 12 National Institute for Health and Care Excellence (NICE). Guidance and guidelines. In: Arthroscopic radiofrequency chondroplasty for discrete chondral defects of the knee. NICE, 2014. https://www.nice. org.uk/guidance/ipg493
- 13 Digital NHS. Statistics HE. Available: http://content.digital.nhs.uk/hes [Accessed 4 Dec 2017].
- 14 Digital NHS. National clinical coding standards. Stationery Office, 2017.
- 15 Digital NHS. Hospital episode statistics (hES) analysis guide, 2015. Available: http://content.digital.nhs.uk/media/1592/HES-analysisguide/pdf/HES\_Analysis\_Guide\_March\_2015.pdf [Accessed 4 Dec 2017].
- 16 HSCIC. Indicator specification. In: Summary hospital-level mortality indicator (SHMI. Version 1.25, 2017. https://www.digital.nhs.uk/SHMI
- 17 Charlson ME, Pompei P, Ales KL, et al. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis 1987;40:373–83.
- 18 Zhang JX, Iwashyna TJ, Christakis NA. The performance of different lookback periods and sources of information for Charlson comorbidity adjustment in Medicare claims. *Med Care* 1999;37:1128–39.
- 19 Noble M, Wright G, Smith G, et al. Measuring multiple deprivation at the Small-Area level. Environ Plan A 2006;38:169–85.
- 20 Abram SGF, Judge A, Beard DJ, *et al.* Temporal trends and regional variation in the rate of arthroscopic knee surgery in England: analysis of over 1.7 million procedures between 1997 and 2017. has practice changed in response to new evidence? *Br J Sports Med* 2019;53:1533–8.
- 21 Loeser RF. Age-Related changes in the musculoskeletal system and the development of osteoarthritis. *Clin Geriatr Med* 2010;26:371–86.
- 22 National Institute for Health and Care Excellence. Arthroscopic knee washout, with or without debridement, for the treatment of osteoarthritis (IPG230). NICE, 2007. Available: https://www.nice.org. uk/guidance/ipg230 [Accessed 8 Jan 2018].
- 23 Boyd JA, Gradisar IM. Total knee arthroplasty after knee arthroscopy in patients older than 50 years. *Orthopedics* 2016;39:e1041–4.
- 24 Judge A, Welton NJ, Sandhu J, *et al*. Equity in access to total joint replacement of the hip and knee in England: cross sectional study. *BMJ* 2010;341:c4092.

# **Open access**

- 25 Adamson J, Ben-Shlomo Y, Chaturvedi N, et al. Ethnicity, socioeconomic position and gender--do they affect reported health-care seeking behaviour? Soc Sci Med 2003;57:895–904.
- 26 Chaturvedi N, Rai H, Ben-Shlomo Y. Lay diagnosis and health-careseeking behaviour for chest pain in South Asians and Europeans. *Lancet* 1997;350:1578–83.
- 27 Jiang L, Tian W, Wang Y, *et al.* Body mass index and susceptibility to knee osteoarthritis: a systematic review and meta-analysis. *Joint Bone Spine* 2012;79:291–7.
- 28 Khan T, Alvand A, Prieto-Alhambra D, *et al*. Acl and meniscal injuries increase the risk of primary total knee replacement for osteoarthritis: a matched case-control study using the

clinical practice research Datalink (CPRD). *Br J Sports Med* 2019;53:965–8.

- 29 Chan SW, Tulloch E, Cooper ES, *et al.* Montgomery and informed consent: where are we now? *BMJ* 2017;357:j2224.
- 30 UK Health Accounts. 2016 Office for National Statistics, 2016. Available: https://www.ons.gov.uk/peoplepopulationandcommunity/ healthandsocialcare/healthcaresystem/bulletins/ukhealthaccounts/ 2016 [Accessed 5 Jun 2018].
- 31 Kraeutler MJ, Belk JW, Purcell JM, *et al.* Microfracture versus autologous chondrocyte implantation for articular cartilage lesions in the knee: a systematic review of 5-year outcomes. *Am J Sports Med* 2018;46:995–9.